Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.72 |
| ▸ | THRB | P10828 | 1/20 | 0.72 |
| ▸ | PPARG | P37231 | 7/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.64 |
| ▸ | AGPAT2 | O15120 | 4/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.59 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4513731 | 0.94 | MAPT (0.76) | MAPTTHRBPPARGPTGS2AGPAT2 | |
| SCHEMBL27188334 | 0.85 | PPARG (0.76) | MAPTTHRBPPARGPTGS2TP53 | |
| SCHEMBL4521584 | 0.85 | MAPT (0.65) | MAPTTHRBPPARGAGPAT2TP53 | |
| SCHEMBL4514083 | 0.83 | MAPT (0.73) | MAPTTHRBAGPAT2TP53 | |
| SCHEMBL4505279 | 0.83 | MAPT (0.58) | MAPTTHRBPPARGAGPAT2 | |
| SCHEMBL27188689 | 0.83 | PPARG (0.79) | MAPTTHRBPPARGPTGS2TP53 | |
| SCHEMBL27188327 | 0.83 | PPARG (0.73) | MAPTTHRBPPARGPTGS2CYP2C8 | |
| SCHEMBL27188332 | 0.82 | PPARG (0.85) | MAPTTHRBPPARGPTGS2TP53 | |
| SCHEMBL31451577 | 0.82 | MAPT (0.70) | MAPTTHRBPPARGPTGS2TP53 | |
| SCHEMBL27188338 | 0.81 | PPARG (0.82) | MAPTTHRBPPARGPTGS2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258917-A1 | Benzoxazoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258917-A1 | Benzoxazoles Useful in the Treatment of Inflammation | IL4I1, EPX, IL4 | MAPT 270/4885THRB 2687/4885PPARG 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.